The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2017
Filed:
Feb. 28, 2013
Applicants:
Indus Pharmaceuticals, Inc., Woburn, MA (US);
Pravin R. Chaturvedi, Andover, MA (US);
Palaniyandi Manivasakam, West Roxbury, MA (US);
Steven Grossman, Richmond, VA (US);
Sharon Cantor, Weston, MA (US);
Inventors:
Pravin R. Chaturvedi, Andover, MA (US);
Palaniyandi Manivasakam, West Roxbury, MA (US);
Steven Grossman, Richmond, VA (US);
Sharon Cantor, Weston, MA (US);
Assignee:
INDUS PHARMACEUTICALS, INC., Woburn, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5517 (2006.01); A61K 45/06 (2006.01); A61K 31/165 (2006.01); A61K 31/337 (2006.01); A61K 31/407 (2006.01); A61K 31/45 (2006.01); A61K 31/4745 (2006.01); A61K 31/475 (2006.01); A61K 31/502 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 33/24 (2006.01); A61K 31/713 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5517 (2013.01); A61K 31/165 (2013.01); A61K 31/337 (2013.01); A61K 31/407 (2013.01); A61K 31/45 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 31/713 (2013.01); A61K 33/24 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); C12N 2310/14 (2013.01);
Abstract
The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent.